Jeremy Sohn

SchoolCare partners with K-12 school nurse offices to seamlessly connect children and their families to healthcare services.

COTA was founded in 2011 by doctors, engineers, and data scientists to create clarity from fragmented and often-inaccessible real-world data. By using our proprietary technology, advanced analytics and deep expertise to organize complex data, we provide a comprehensive picture of cancer that can be used to advance care and research. ‍We believe that everyone touched by cancer deserves a clear path to care. Together, we can make that vision a reality.

In 2023 NeuraSignal, Inc. acquired the business of NovaSignal, the original developer of NovaGuide. NeuraSignal is a medical technology company with a mission to save lives by unlocking the power of cerebral blood flow data. The company’s FDA-cleared NovaGuide Intelligent Ultrasound combines non-invasive ultrasound, robotics, and artificial intelligence to assess cerebral hemodynamics in real time. Using cloud computing and data analytics, NeuraSignal supports physicians in their clinical decision making in several neurological conditions including stroke, traumatic brain injury, and dementia. To learn more, visit www.NeuraSignal.com.

Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

Clinical ink is the global life science company that brings data, technology, and patient-centric research together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.

BenevolentAI was founded in 2013 to improve quality of life and protect our way of life through technology. That belief has guided everything weve built. Today, theres more scientific knowledge being created than any human can process. We build AI systems that help humanity make sense of it - technology that can read, reason across, and explain the worlds biomedical knowledge. Our approach proved its value when our AI identified baricitinib as a potential Covid-19 treatment within 48 hours, a drug that went on to save lives globally. That wasnt about replacing scientists but extending what they could achieve. Now were making that capability accessible to the broader life sciences ecosystem through Qor, our strategic decision intelligence platform for biotech leaders. Technology in service of life. BenevolentAI is headquartered in London, UK.

VuuAI transforms commercial and medical engagement using AI-powered automation to empower pharma and medtech teams to efficiently produce compliant, on-brand, and effective content, thereby accelerating the adoption of medical innovation.

P74 Ventures is uniquely positioned to be the “Flagship Pioneering” for the Pharma-Tech venture community -- focused on both founding and investing in technology companies that drive innovation and business model transformation within the $1.5 trillion life sciences industry. While most healthcare VCs focus on either biotech or the broader digital health landscape, few, if any, have the expertise to invest in the enabling technologies that drive the business & operations of pharma. Even fewer, have the ability to also co-found companies targeting the core challenges in this space. Together, P74’s Managing Partners have been at the forefront of pharma’s innovation efforts for the last decade – starting companies and then leading digital investments, global innovation, business model transformation, strategic corporate partnerships, and data science and AI at the #3 pharma company in the world, Novartis. As leading experts in the field, P74’s Fund Managers believe they can continue to achieve alpha returns by investing in and/or co-founding early-stage companies targeting problems and markets where the Team has deep experience and where at least one pharma will be a founding partner, paying customer, and/or co-development collaborator. Over the last few years alone, the team has completed 26 investments (with 3 IPOs/SPACs), founded 3 companies (with 2 PE exits), led partnerships with over 85 startups and industry-leading tech companies, and developed 8 transformational technology platforms for big-pharma.